Shilpa Medicare introduces new anticancer drug to India

It has just become known to the markets that 'IBRUSHIL', an anti-cancer drug has been launched in the Indian market by pharmaceutical company, Shilpa Medicare Limited.

IBRUSHIL is majorly used in the treatments of patients suffering from Mantle Cell Lymphomas (MCL), Chronic Lymphocytic Leukemia (CLL) and other related cancers. The company stated that this new drug is very effective as it directly attacks cancer cells without harming normal cells.

Now, the monthly cost of the treatment will reduce from Rs 4.36 lakh to Rs 34,920, with the launch of IBRUSHIL.

This is Shilpa Medicare's third launch of an anticancer drug in the Indian market followed by the successful launch of Lenvatinib "LENSHIL" and Dasatinib "DASASHIL".

Shilpa Medicare Limited (SML) is a global brand engaged in manufacturing of bulk drugs or Active Pharmaceutical Ingredient (API).

In response to this development, Shilpa Medicare's stock rallied nearly five per cent and made an intraday high of Rs 388.50 on BSE.